WCN26-2195 WHOLE BLOOD RNASEQ PROFILING IDENTIFIED FUNCTIONALLY ENRICHED GENE EXPRESSION PATTERNS IN FELZARTAMAB-TREATED PATIENTS WITH IGA NEPHROPATHY: DATA FROM THE PHASE 2 IGNAZ STUDY

Read full text Summarise with VIRAT
Authors: Millie Shah, Yirui Chen, Tess Arenzana Delfino, Lisa Kivman, Tabea Kräft, Leslie W. Chinn, Brian M. Schwartz, Nicholas S. Jones, Valeria V. Beckett, Uptal D. Patel, Donna Flesher, Jonathan Barratt
+1 more Krzysztof Kiryluk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Felzartamab, a fully human anti-CD38 monoclonal antibody targeting CD38+ plasmablasts and plasma cells, reduced proteinuria and stabilized eGFR in patients with IgA nephropathy (IgAN) in the Phase 2 IGNAZ study (NCT05065970). We used whole blood RNAseq profiling to examine gene expression patterns in felzartamab-treated patients with IgAN.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Multiple Myeloma Research and Treatments Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104422–104422
Publication date
25 March 2026
Language
EN